Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer

Sathianathen, Niranjan; Oestreich, Makinna; Brown, Sarah Jane; Gupta, Shilpa; Konety, Badrinath R.; Dahm, Philipp; Kunath, Frank

doi:10.1002/14651858.cd013245.pub2

Cited by 5 publications

(3 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no statistical difference in ATT exposure to ALS risk in the overall ATT unadjusted population (Table 3). In the propensity score-adjusted population, statistical differences were sustained for NDD (10,170 S1. Kaplan-Meier survival curves for NDD-free survival for each NDD subtype were generated using propensity score-matched population data to evaluate incidence rate and percent of population for each disease (Figure S2).…”

Section: Resultsmentioning

confidence: 94%

“…2 In 2022, 268,490 new cases of prostate cancer are expected to be diagnosed in the U.S.. 2 Androgen deprivation therapy has been effectively used for the treatment of prostate cancer for more than 75 years. [3][4][5][6][7][8] Gonadotrophin-releasing hormone (GnRH) agonists (leuprolide, goserelin, triptorelin, and histrelin) and GnRH antagonists (degarelix) constitute the drug class of androgen deprivation therapy (ADT) in the U.S. 3,8,9 Recently, androgen synthesis inhibitors (ketoconazole and abiraterone) 10,11 or androgen receptor (AR) inhibitors (flutamide, bicalutamide, nilutamide, and enzalutamide) 12,13 were added to improve the efficacy of GnRH agonists and antagonists. 14 Although abiraterone's mechanism of action is different from direct AR blockade, the clinical benefits have been indistinguishable from thirdgeneration AR antagonists despite the absence of direct comparisons in clinical trials.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer

et al. 2022

View full text Add to dashboard Cite

Background Prostate cancer and multiple neurodegenerative diseases (NDD) share an age‐associated pattern of onset. Therapy of prostate cancer is known to impact cognitive function. The objective of this study was to determine the impact of multiple classes of androgen‐targeting therapeutics (ATT) on the risk of NDD. Methods A retrospective cohort study of men aged 45 and older with prostate within the US‐based Mariner claims data set between January 1 and 27, 2021. A propensity score approach was used to minimize measured and unmeasured selection bias. Disease risk was determined using Kaplan–Meier survival analyses. Results Of the 1,798,648 men with prostate cancer, 209,722 met inclusion criteria. Mean (SD) follow‐up was 6.4 (1.8) years. In the propensity score‐matched population, exposure to ATT was associated with a minimal increase in NDD incidence (relative risk [RR], 1.07; 95% CI, 1.05–1.10; p < 0.001). However, GnRH agonists alone were associated with significantly increased NDD risk (RR, 1.47; 95% CI, 1.30–1.66; p <0.001). Abiraterone, commonly administered with GnRH agonists and low‐dose prednisone, was associated with a significantly decreased risk (RR, 0.77; 95% CI, 0.68–0.87; p < 0.001) of any NDD. Conclusions Among patients with prostate cancer, GnRH agonist exposure was associated with an increased NDD risk. Abiraterone acetate reduced the risks of Alzheimer's disease and Parkinson's disease conferred by GnRH agonists, whereas the risk for ALS was reduced by androgen receptor inhibitors. Outcomes of these analyses contribute to addressing controversies in the field and indicate that GnRH agonism may be a predictable instigator of risk for NDD with opportunities for risk mitigation in combination with another ATT.

show abstract

Section: Resultsmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Androgen‐targeting therapeutics mitigate the adverse effect of GnRH agonist on the risk of neurodegenerative disease in men treated for prostate cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…This new endocrine therapy targets specific molecules or signaling pathways in PCa cells to inhibit their proliferation. It includes two types of drugs that target the androgen receptor (AR) signal transduction pathway: androgen synthesis inhibitors, such as abiraterone [14][15][16] , and AR inhibitors, which belong to a new type of non-steroidal anti-androgen drugs, such as enzalutamide [17][18][19] and apalutamide 20,21 . Compared with traditional endocrine therapy, these drugs exhibit higher targeting and selectivity, which can delay the progression of PCa and improve safety.…”

Section: Introductionmentioning

confidence: 99%

A bibliometric analysis of global research status and trends in novel endocrine therapy in the treatment of prostate cancer (Preprint)

Yang,

Miao,

et al. 2024

Preprint

View full text Add to dashboard Cite

BACKGROUND Novel endocrine therapy for prostate cancer is developing rapidly and has gradually become a research hotspot in the field of prostate cancer treatment. OBJECTIVE Objective: This study aims to provide a comprehensive bibliometric analysis of novel endocrine therapies for prostate cancer (PCa), offering insight into the current research status, hotspots, and emerging trends in the field to inspire further exploration. METHODS Method: Data were extracted from the Web of Science core collection (WoSCC) database, with primary analysis utilizing data visualization tools VOSviewer and CiteSpace. A systematic and visual analysis was conducted, generating visual representations of data points such as publication volumes, countries, institutions, authors, journals, cited references, and keywords. RESULTS Result: The analysis covered a total of 2452 publications and identified an upward trend in novel endocrine treatments for PCa research over the past two decades. The United States leads in research contribution with a total of 1106 publications. The University of British Columbia had the highest volume of publications, while the author, Scher, Howard, was cited most often. The Journal of Clinical Oncology emerged as a pivotal journal in this field. The most-cited reference was found in The New England Journal of Medicine. Notable research hotspots are inclusive of 'docetaxel', 'metastatic castration-resistant prostate cancer', 'lineage plasticity', and 'PSMA'. CONCLUSIONS Conclusion: The increasing engagement of scholars in novel endocrine therapies for PCa research and the strong collaborative ties between different countries, institutions, and authors advocate rapid advancement in this field. The current study reveals the evolution of novel endocrine treatments for PCa and identifies emerging research hotspots, primarily centered around 'docetaxel', 'advanced castration-resistant prostate cancer', 'lineage plasticity', and 'Prostate-Specific Membrane Antigen (PSMA)'.

show abstract